Antibodies reactive with B7-H3 and users thereof
US10730945B2 · kind B2 · utility
0Cited by
127References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 4, 2018 |
| Grant date | Aug 4, 2020 |
| Priority date | — |
| Expiry date | Nov 12, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.